Get the Stockscreener App
0.7707
3.05%
-0.0242
Oncolytics Biotech Inc stock is traded at $0.7707, with a volume of 473.44K.
It is down -3.05% in the last 24 hours and down -15.73% over the past month.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatment. The other projects in the company's pipeline include, Bracelet-1 for treatment of Breast Cancer, Goblet cohort-1, Goblet cohort-5 for treatment of Gastro-Intestinal Cancer among others.
See More
Previous Close:
$0.7949
Open:
$0.8054
24h Volume:
473.44K
Relative Volume:
0.41
Market Cap:
$61.27M
Revenue:
-
Net Income/Loss:
$-20.31M
P/E Ratio:
-2.9136
EPS:
-0.2645
Net Cash Flow:
$-21.07M
1W Performance:
+5.71%
1M Performance:
-15.73%
6M Performance:
-22.56%
1Y Performance:
-13.71%
1-Day Range:
$0.76
$0.8096
1-Week Range:
$0.67
$0.84
52-Week Range:
$0.67
$1.53
Oncolytics Biotech Inc Stock (ONCY) Company Profile
Compare ONCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
0.7688 | 61.27M | 0 | -20.31M | -21.07M | -0.2645 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.04 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.08 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.89 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.69 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.71 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-22 | Initiated | Maxim Group | Buy |
| Feb-17-21 | Initiated | H.C. Wainwright | Buy |
Oncolytics Biotech Inc Stock (ONCY) Latest News
Oncolytics Biotech And 2 Other Promising Penny Stocks On The TSX - Simply Wall St
Oncolytics Biotech (TSE:ONC) Reaches New 12-Month LowTime to Sell? - MarketBeat
Equities Analysts Offer Predictions for ONCY FY2024 Earnings - Defense World
Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
H.C. Wainwright maintains $5 target on Oncolytics Biotech stock - MSN
Can you now get a good deal on Oncolytics Biotech, Inc’s shares? - US Post News
What is HC Wainwright's Estimate for ONCY FY2024 Earnings? - MarketBeat
FY2029 Earnings Forecast for ONCY Issued By HC Wainwright - Defense World
FY2029 Earnings Forecast for TSE:ONC Issued By HC Wainwright - Defense World
Oncolytics Biotech (NASDAQ:ONCY) Earns “Buy” Rating from HC Wainwright - Defense World
Financial Metrics Exploration: Understanding Oncolytics Biotech, Inc (ONCY) Through Ratios - The Dwinnex
Brokers Offer Predictions for ONCY FY2029 Earnings - MarketBeat
FY2029 Earnings Estimate for TSE:ONC Issued By HC Wainwright - MarketBeat
H.C. Wainwright maintains $5 target on Oncolytics Biotech stock By Investing.com - Investing.com South Africa
HC Wainwright Reaffirms Buy Rating for Oncolytics Biotech (NASDAQ:ONCY) - MarketBeat
Oncolytics Biotech’s Pelareorep Advances: Promising Phase 2 Results and Regulatory Momentum Affirm Buy Rating - TipRanks
Oncolytics Biotech (TSE:ONC) Sets New 52-Week LowHere's What Happened - MarketBeat
Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium - The Malaysian Reserve
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - The Globe and Mail
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastroin - GuruFocus.com
Oncolytics Biotech to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers At 2025 Asco GI Symposium - Marketscreener.com
Oncology Experts Predict 2025 Will Be a Year of Breakthroughs in Treatment and Prevention - Baystreet.ca
USA News Group: Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium - finanznachrichten.de
Guardant Health Inc (GH-Q) QuotePress Release - The Globe and Mail
Demand for Advanced Pancreatic Cancer Treatments at All Time High as Promising Options Come into Focus - GlobeNewswire
Oncolytics Biotech Presents Promising Cancer Treatment Data - TipRanks
German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial - MSN
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | CG Oncology, Targovax, Transgene, Istari Oncology, Targovax, Oncolytics Biotech - The Globe and Mail
Oncolytic Virus Cancer Therapy Pipeline 2024: Therapies, MOA - openPR
Oncolytics Biotech (TSE:ONC) Shares Down 3.4%What's Next? - MarketBeat
Oncolytics Biotech Inc. Announces Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data - Marketscreener.com
Oncolytics Bio (ONC-T) QuotePress Release - The Globe and Mail
Stocks In Play: Oncolytics Biotech Inc - Barchart
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Lelezard
Regulatory Approval Clears Path for Oncolytics Biotech® to Advance Promising Pancreatic Cancer Treatment, Following a Review of Safety Data - Barchart
Oncolytics Biotech (TSE:ONC) Trading Down 3.4%Time to Sell? - MarketBeat
Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year - Benzinga
Investors Eye Biotech Stocks as Cancer Therapies Take Center Stage in 2025 - Baystreet.ca
Oncolytics Biotech Inc - Baystreet.ca
Regulatory Approval Clears Path for Oncolytics Biotech® to Advan - GuruFocus.com
Oncolytics Biotech Advances Pancreatic Cancer Treatment with Regulatory Approval - TipRanks
Oncolytics Biotech (TSE:ONC) Share Price Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
Oncolytics Biotech (TSE:ONC) Shares Pass Below 200-Day Moving Average – Here’s Why - Defense World
A Data-Based Look At Oncolytics Biotech, Inc (ONCY) - Stocks Register
Oncolytics Biotech® to Host Conference Call to Discuss First Qua - GuruFocus.com
Suncor Energy Inc (SU-N) QuotePress Release - The Globe and Mail
Oncolytics Biotech (NASDAQ:ONCY) Stock Price Up 3.2% – Still a Buy? - Defense World
Oncolytics Biotech (TSE:ONC) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Oncolytics Biotech (NASDAQ:ONCY) Trading Up 3.2%What's Next? - MarketBeat
Will Oncolytics Biotech (TSE:ONC) Spend Its Cash Wisely? - Yahoo Finance
Oncolytics Biotech (TSE:ONC) Stock Crosses Above 200-Day Moving AverageShould You Sell? - MarketBeat
Oncolytics Biotech Inc Stock (ONCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):